



June 7, 2004

The Honorable Bill Frist, M.D.
United States Senate
Washington, D.C. 20510

Dear Majority Leader Frist:

We, the undersigned biotechnology executives, strongly oppose further efforts to legalize prescription drug importation. Importation will put patients at risk, chill investment in biotechnology and other pharmaceutical research and development, and threaten intellectual property protections.

First, legalizing importation will place patients at risk of obtaining products that do not meet the FDA standards that patients have relied upon for decades. Since biotechnology products are unique, many are particularly susceptible to adulteration, degradation and virtually undetectable counterfeiting. Many cannot be administered safely by the patient, but require intervention and/or supervision of a health care provider. BIO believes that the importation of non-biotechnology products could increase the availability of unsafe or ineffective biotechnology products.

Second, efforts to legalize importation (and to import foreign price controls) will have a negative impact on biotechnology investment. The cost and time to develop a new pharmaceutical product is generally agreed to be more than \$800 million and 12-15 years; the costs and time to develop a new biotechnology product can be substantially greater. Since many biotechnology companies do not have the financial underpinning provided by multiple profitable products already on the market, they rely on maintaining a high rate of capital investment for long periods of time – investment that is made based on an expectation of a healthy return. National or local policy changes that affect the potential viability of the biotechnology market (via price controls or any other means) will affect the willingness of investors to take this risk.

1225 EYE STREET, N.W., SUITE 400
WASHINGTON, D.C. 20005-5958

202-962-9200
FAX 202-962-9201
<http://www.bio.org>

June 7, 2004

Page Two

Third, prescription drug importation legislation will erode intellectual property rights. One bill would prevent U.S. manufacturers from enforcing their patents against foreign products that, if marketed in the U.S. under current law, would violate the patent on the U.S. product. Even though the foreign product is imported into the U.S. market in direct competition with the U.S. FDA-approved drug, the manufacturer would be denied recourse under U.S. patent laws. The impact on the biotechnology industry of such a change to patent rights would be enormous.

Finally, although efforts to legalize importation are intended as a mechanism to lower the price of prescription drugs, the Congressional Budget Office and numerous economists have challenged the assumptions of substantial cost savings, noting both the unique features of the world pharmaceutical marketplace and the substantial costs incurred by intermediaries in the proposed import/export scheme that certainly would be passed along to patients. Moreover, recently introduced bills would impose numerous requirements that were not even envisioned by the economists who looked at earlier legislation, so transaction costs under these proposals would be significantly higher. Additionally, examination by economists of European parallel imports shows that the expected significant savings for consumers have not materialized, although the traders have realized tidy profits. None of the bills recently introduced guarantee that the cost differential for the importer/exporter actually would be passed along to the consumer.

We urge you to oppose further importation legislation. Importation measures will harm the biotechnology industry and will, more importantly, harm the patients we are dedicated to help. Legalizing importation is not the answer to improving access to prescription drugs. Its promise is false and its dangers are real.

Sincerely

Richard F. Pops
Chairman of the Board, BIO
CEO
Alkermes, Inc.
Cambridge, Massachusetts

Carl B. Feldbaum
President
**Biotechnology Industry
Organization**
Washington, D.C.

June 7, 2004

Page Three

Bob Booth
President and General Manager
Axcan Scandipharm, Inc.
Birmingham, Alabama

Charles E. Bugg, Ph.D.
CEO
BioCryst Pharmaceuticals, Inc.
Birmingham, Alabama

Mike Allen
President & CEO
International Medical Innovations
Birmingham, Alabama

Duane J. Roth
Chairman & CEO
Alliance Pharmaceutical Corporation
San Diego, California

Kleanthis G. Xanthopoulos, Ph.D.
President & CEO
Anadys Pharmaceuticals
San Diego, California

John P. Walker
Chairman
Bayhill Therapeutics, Inc.
Palo Alto, California

David Gollaher
President & CEO
California Healthcare Institute (CHI)
La Jolla, California

Richard W. Hamilton
President & CEO
Ceres, Inc.
Malibu, California

Tom Wiggins
President & CEO
Connetics Corporation
Palo Alto, California

Jay M. Short, Ph.D.
President & CEO
Diversa Corporation
San Diego California

John Martin
President & CEO
Gilead Sciences, Inc.
Foster City, California

Steve Boggan
CEO
BioHorizons
Birmingham, Alabama

Royce L. Watkins
President & CEO
Cebert Pharmaceuticals, Inc.
Birmingham, Alabama

Lawrence W. Greer
President
SCOUT Corporation
Birmingham, Alabama

Dennis M. Fenton
EVP, Operations & Compliance Officer
Amgen, Inc.
Thousand Oaks, California

Gerald J. Yakatan, Ph.D.
President & CEO
Avanir Pharmaceuticals
San Diego, California

Joseph D. Panetta
President & CEO
BIOCOM
San Diego, California

David F. Hale
President & CEO
CancerVax Corporation
Carlsbad, California

Howard Pien
CEO
Chiron Corporation
Emeryville, California

A. Stephen Dahms
Executive Director
CSUPERB
San Diego, California

Dan Browne
President & CEO
Essentia Biosystems, Inc.
Mountain View, California

Evan B. Siegel, Ph.D.
President & CEO
Ground Zero Pharmaceuticals, Inc.
Irvine, California

Mike Alder
Executive Director
Biotechnology Association of Alabama
Birmingham, Alabama

Dante J. Marciani
President & CEO
Galenica Pharmaceuticals, Inc.
Birmingham, Alabama

David E.I. Pyott
Chairman, President and CEO
Allergan, Inc.
Irvine, California

Ginger L. Graham
President & CEO
Amylin Pharmaceuticals
San Diego, California

Matt Gardner
President
BayBIO
South San Francisco, California

Frederic D. Price
CEO & Chairman
BioMarin Pharmaceuticals, Inc.
Novato, California

Stephen A. Sherwin, M.D.
Chairman & CEO
Cell Genesys, Inc.
South San Francisco, California

Lawrence C. Fritz
President & CEO
Conforma Therapeutics Corporation
San Diego, California

Louis G. Lange
Chairman & CEO
CV Therapeutics, Inc.
Palo Alto, California

Thomas Okarma
President & CEO
Geron Corporation
Menlo Park, California

Steven J. Mento, Ph.D.
President & CEO
Idun Pharmaceuticals
San Diego, California

June 7, 2004

Page Four

Gregory T. Lucier
Chairman & CEO
Invitrogen Corporation
Carlsbad, California

David E. Robinson
President, CEO and Chairman
Ligand Pharmaceuticals
San Diego, California

Robert Chess
Chairman
Nektar Therapeutics
San Carlos, California

Hollings C. Renton
Chairman & CEO
Onyx Pharmaceuticals
Richmond, California

James Mitchell
President
Scios, Inc.
Fremont, California

Rick E. Winningham
CEO
Theravance
South San Francisco, California

John L. Castello
Chairman, President & CEO
Xoma, Ltd.
Berkeley, California

Colin Foster
President and Head, North America,
Bayer Pharmaceuticals
West Haven, Connecticut

David R. Brennan
President & CEO
AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware

John Spencer, Jr.
President
Georgia Biomedical Partnership, Inc.
Atlanta, Georgia

Norbert Riedel
SVP, Chief Scientific Officer
Baxter International, Inc.
Deerfield, Illinois

Martin D. Cleary
President & CEO
Juvaris BioTherapeutics, Inc.
Pleasanton, California

Larry G. Stambaugh
Chairman, President & CEO
Maxim Pharmaceuticals
San Diego, California

Paul Freiman
President & CEO
Neurobiological Technologies, Inc.
Richmond, California

Jennie P. Mather
CEO
Raven Biotechnologies
South San Francisco, California

Timothy J.R. Harris, Ph.D.
CEO
Structural GenomiX, Inc.
San Diego, California

David V. Goeddel
CEO
Tularik, Inc.
South San Francisco, California

Denise Brown
Executive Director
Colorado BioScience Association
Aurora, Colorado

Paul R. Pescatello
President & CEO
**Connecticut United for Research
Excellence (CURE)**
New Haven, Connecticut

Thomas McLain
Chairman, CEO and President
Nabi Biopharmaceuticals
Boca Raton, Florida

William D. Johnston, Ph.D.
President & CEO
Inhibitex, Inc.
Alpharetta, Georgia

James Hussey, MBA
President/CEO
NeoPharm, Inc.
Lake Forest, Illinois

Lewis J. Shuster
CEO
Kemia, Inc.
San Diego, California

Walter H. Moos
Chairman & CEO
Mitokor, Inc.
San Diego, California

Ted W. Love, M.D.
President & CEO
Nuvelo, Inc.
Sunnyvale, California

Edward Lanphier
President & CEO
Sangamo BioSciences, Inc.
Richmond, California

Jeffrey N. Peterson
CEO
Target Discovery, Inc.
Palo Alto, California

Benjamin F. McGraw
Chairman, President & CEO
Valentis, Inc.
Burlingame, California

Timothy C. Rodell, M.D.
CEO
GlobeImmune, Inc.
Aurora, Colorado

Kevin Rakin
President & CEO
Genaissance Pharmaceuticals
New Haven, Connecticut

Charles A. Rice
President & CEO
Viragen, Inc.
Plantation, Florida

David Miller
President & CEO
Illinois Biotechnology Association
Chicago, Illinois

Sidney Taurel
Chairman, President, & CEO
Eli Lilly & Company
Indianapolis, Indiana

June 7, 2004

Page Five

Vickie Hall
Vice President of Iowa Operations
Fort Dodge Animal Health
Fort Dodge, Iowa

Kenneth C. Carter, Ph.D.
President & CEO
Avalon Pharmaceuticals
Germantown, Maryland

William A. Haseltine, Ph.D.
Chairman and CEO
Human Genome Sciences, Inc.
Rockville, Maryland

David Mott
CEO, President & Vice Chairman
MedImmune, Inc.
Gaithersburg, Maryland

Dyan Brasington
President
Technology Council of Maryland
Rockville, Maryland

James C. Mullen
CEO & President
Biogen Idec, Inc.
Cambridge Massachusetts

Geoffrey F. Cox
Chairman, President & CEO
GTC Biotherapeutics, Inc.
Framingham, Massachusetts

Mark Levin
Chairperson, President, and CEO
Millennium Pharmaceuticals, Inc
Cambridge, Massachusetts

Fereydoun Firouz
President
Serono, Inc.
Rockland, Massachusetts

Christopher Perley
Managing Director
Wyeth Pharmaceuticals
Andover, Massachusetts

James V. Adam
CEO
Blizzard Genomics, Inc.
St. Paul, Minnesota

Doug Getter
Executive Director
Iowa Biotechnology Association
Urbandale, Iowa

Shirley Gotner-Arnowitz
Chief Operating Officer
BSI Proteomics Corporation
Gaithersburg, Maryland

Douglas A. Doerfler
President & CEO
MaxCyte, Inc.
Rockville, Maryland

David P. Wright
President & CEO
Pharmathene, Inc.
Annapolis, Maryland

Russell Herndon
President
Antigenics, Inc.
Lexington, Massachusetts

Michael Webb
CEO & President
EPIX Medical, Inc.
Cambridge, Massachusetts

Mitchel Sayare
Chairman & CEO
ImmunoGen, Inc.
Cambridge, Massachusetts

Steven M. Rauscher
President & CEO
Oscient Pharmaceuticals Corporation
Waltham, Massachusetts

Garen Bohlin
President & CEO
Syntonix Pharmaceuticals, Inc.
Waltham, Massachusetts

Duffy DuFresne
President & CEO
Zelos Therapeutics
Waltham, Massachusetts

Ray Frost
Executive Director
**Minnesota Biotechnology Association
(MNBIO)**
Saint Paul, Minnesota

Alex Day
CEO
Sheltowee, LLC
Louisville, Kentucky

Rachel K. King
Chief Executive Officer
GlycoMimetics, Inc.
Gaithersburg, Maryland

C. Robert Eaton
President
MdBio, Inc.
Frederick, Maryland

Carol A. Nacy, Ph.D.
CEO
Sequella, Inc.
Rockville, Maryland

Una S. Ryan Ph.D.
President & CEO
AVANT Immunotherapeutics, Inc.
Needham, Massachusetts

Henri A. Termeer
Chairman & CEO
Genzyme Corporation
Cambridge, Massachusetts

Mark Trusheim
President
Massachusetts Biotechnology Council
Cambridge, Massachusetts

Diedre Gillespie, M.D., M.B.A.
President & CEO
Oxxon Therapeutics
Boston, Massachusetts

Joshua Boger Ph.D.
Chairman & CEO
Vertex Pharmaceuticals Inc.
Cambridge, Massachusetts

Michael Witt
Executive Director
MichBio
Ann Arbor, Michigan

Bill Romjue
President & CEO
Missouri Biotechnology Association
Jefferson City, Missouri

June 7, 2004

Page Six

David Sethman
Manager
Wyeth Pharmaceuticals
Sparks, Nevada

John Jackson
CEO & Chairman of the Board
Celgene Corporation
Warren, New Jersey

Martin Soeters
President
Novo Nordisk Pharmaceuticals, Inc.
Princeton, New Jersey

George Abercrombie
President & CEO
**Roche North American
Pharmaceuticals Operations**
Nutley, New Jersey

Göran Ando, M.D.
CEO
Celltech Group, plc
Rochester, NY

Timothy Cooke
CEO
Mojave Therapeutics, Inc.
Hawthorne, New York

Lynne H. Parker
Managing Partner
Trillium Medical Partners
New York, New York

Joseph Akers
President
Bayer Biological Products
Research Triangle Park, North Carolina

Chris Viehbacher
President, U.S. Pharmaceuticals
GlaxoSmithKline
Research Triangle Park, North Carolina

J. Bruce Kaylos
Managing Director
Wyeth Vaccines
Sanford, North Carolina

Debbie Hart
President
Biotechnology Council of New Jersey
Trenton, New Jersey

Bruce A. Williams
Senior Vice President
Genta Incorporated
Berkeley Heights, New Jersey

John H. Johnson
President
Ortho Biotech Products
Bridgegewater, New Jersey

George A. Oram
President & CEO
Tissue Transformation Technologies
Edison, N.J.

Gary K. Zammit, Ph.D.
President & CEO
Clinilabs, Inc.
New York, New York

Karin A. Duncker
Executive Director
**New York Biotechnology Association
(NYBA)**
New York, New York

Michael P. McDermott
Managing Director, Vaccines
Wyeth Pharmaceuticals
Pearl River, New York

Scott Uknes
President
Cropsolution
Morrisville, North Carolina

Clint G. Dederick, Jr.
CEO, President, Chairman
Merix BioScience, Inc.
Durham, North Carolina

Gil Van Bokkelen
CEO
Athersys, Inc.
Cleveland, Ohio

James B. Palmer, M.D.
Chief Scientific Officer & President,
Pharmaceutical Research Institute
Bristol-Myers Squibb Company
Princeton, New Jersey

Joseph C. Scodari
Company Group Chairman,
Biopharmaceuticals
Johnson & Johnson
New Brunswick, New Jersey

Robert Pestka
President & CEO
PBL Therapeutics
Piscataway, New Jersey

Ron Cohen
President & CEO
Acorda Therapeutics
Hawthorne, New York

Frederick Frank
Vice Chairman
Lehman Brothers, Inc.
New York, New York

Fred Telling
Vice President, Corporate Policy and
Strategic Management
Pfizer, Inc.
New York, New York

Peter F. Young
President & CEO
AlphaVax, Inc.
Research Triangle Park, North Carolina

Nancy Wysenski
President
EMD Pharmaceuticals, Inc.
Durham, North Carolina

J. Donald deBethizy, Ph.D.
President & CEO
Targacept, Inc.
Winston-Salem, North Carolina

Anthony J. Dennis
CEO & President
Omeris
Columbus, Ohio

June 7, 2004

Page Seven

Bruce A. Peacock
President & CEO
Adolor Corporation
Exton, Pennsylvania

Frank Baldino, Jr.
Chairman & CEO
Cephalon, Inc.
West Chester, Pennsylvania

Fritz Bittenbender
President
Pennsylvania Biotechnology Association
Malvern, Pennsylvania

Robert R. Ruffolo, Jr.
President
Wyeth Pharmaceuticals
Collegeville, Pennsylvania

Dennis Grimaud
President
Tennessee Biotechnology Association
Nashville, Tennessee

Michael T. Redman
President & CEO
Opexa Pharmaceuticals, Inc.
Houston, Texas

Peter D. Meldrum
President and CEO
Myriad Genetics, Inc.
Salt Lake City, Utah

Randal Hassler
Vice President, Operations
Amgen, Inc.
Seattle, Washington

Albert A. Luderer, Ph.D.
President & CEO
Light Science Corporation
Snoqualmie, Washington

Bruce L.A. Carter
President & CEO
ZymoGenetics, Inc.
Seattle, Washington

Raymond K. Houck
President & CEO
Automated Cell, Inc.
Pittsburg, Pennsylvania

David W. Anstice
President, Human Health
Merck & Co., Inc.
North Wales, Pennsylvania

William B. Wiederseim
President & CEO
Pharma BioSource, Inc.
Wayne Pennsylvania

David Bengston
Vice President and General Manager,
Rhode Island Operations
Amgen, Inc.
West Greenwich, Rhode Island

Patrick B. Flanagan
Distribution Center Director
Wyeth Pharmaceuticals
Vonore, Tennessee

Nancy Chang
President & CEO
Tanox, Inc.
Houston, Texas

Brian H. Moss
Director
Utah Life Science Association
Salt Lake City, Utah

Erick Rabins
President & COO
Dentigenix, Inc.
Seattle, Washington

Steven C. Quay, M.D., Ph.D.
Chairman, President & CEO
Nastech Pharmaceutical Company
Bothell, Washington

Tony Vernon
President
Centocor
Horsham, Pennsylvania

C. Boyd Clarke
President, CEO & Chairman of the Board
Neose Technologies
Horsham, Pennsylvania

Mickey Flynn
President
Puresyn, Inc.
Malvern, Pennsylvania

Anthony Boccanfuso
Chairman
Palmetto Biotechnology Alliance
Greenwood, South Carolina

David Anderson
President & CEO
MithraGen, Inc.
Houston, Texas

Tom Kowalski
President
Texas Healthcare & Bioscience Institute
Austin, Texas

Mark Herzog
Executive Director
Virginia Biotechnology Association
Richmond, Virginia

Paul Clark
Chairman & CEO
ICOS Corporation
Bothell, Washington

Ruth M. Scott
President
Washington Biotechnology & Biomedical Association
Seattle, Washington